Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis

Stergios A Polyzos; Antonis Goulas; Paraskevi Papaioannidou

doi:10.2174/0929867330666230106103202

Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis

Curr Med Chem. 2023;30(22):2476-2479. doi: 10.2174/0929867330666230106103202.

Authors

Stergios A Polyzos¹, Antonis Goulas¹, Paraskevi Papaioannidou¹

Affiliation

¹ First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece.

PMID: 36617715
DOI: 10.2174/0929867330666230106103202

No abstract available

Keywords: Diabetes; fibrosis; glucagon-like peptide-1 receptor agonists; glucose-dependent insulinotropic polypeptide; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; obesity; tirzepatide.

Publication types

Editorial

MeSH terms

Diabetes Mellitus*
Diabetes Mellitus, Type 2*
Gastric Inhibitory Polypeptide
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents / therapeutic use
Non-alcoholic Fatty Liver Disease* / drug therapy
Obesity / drug therapy

Substances

tirzepatide
Gastric Inhibitory Polypeptide
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents